Asset Details
Do you wish to reserve the book?
Pregnant persons perceptions and uptake of prenatal RSV vaccine – Minnesota, 2023–2024
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Pregnant persons perceptions and uptake of prenatal RSV vaccine – Minnesota, 2023–2024
Do you wish to request the book?
Pregnant persons perceptions and uptake of prenatal RSV vaccine – Minnesota, 2023–2024
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Pregnant persons perceptions and uptake of prenatal RSV vaccine – Minnesota, 2023–2024
2025
Overview
Respiratory syncytial virus (RSV) vaccine was recommended for use during pregnancy in September 2023.
To assess pregnant persons' intentions to receive and evaluate factors associated with RSV vaccine intentions and uptake.
We invited 1999 pregnant persons ≥18 years, between 12 and 30 weeks gestation who had received prenatal care at HealthPartners to complete an online survey during September–November 2023. Our primary outcome was intention to receive RSV vaccine. We also asked respondents about reasons to or not to receive RSV vaccine and intentions to receive other vaccines during pregnancy. We assessed RSV vaccine uptake for patients 32–36 weeks gestation between 10/12/23 (first RSV vaccine in study population) and 2/1/24. We estimated adjusted prevalence ratios (aPR) and 95 % confidence intervals (CI) between responses and intention to receive RSV vaccination and, for those eligible to receive RSV vaccine, adjusted rate ratios (aRR) and 95 % CIs for RSV vaccine uptake.
We adjusted aPRs and aRRs for age, race, ethnicity, Medicaid, living with children ≤5 years, and work in healthcare and weighted by inverse probability of survey participation using Poisson regression with robust variance.
455 patients participated (23 % response), 26 % were non-white and/or Hispanic, 46 % lived with children ≤5 years, and 30 % work in healthcare; 65 % intended to receive RSV vaccine during pregnancy. Among 427 eligible respondents, 51 % received RSV vaccine. Factors associated with RSV vaccination intention and uptake included perceived vaccine effectiveness (aPR: 19.47, 95 % CI: 5.82, 65.12; aRR 3.06, 95 % CI: 1.70, 5.51) and a provider recommendation (aPR: 8.04, 95 % CI: 4.23, 15.29; aRR 3.30, 95 % CI: 1.99, 5.48). Among those not planning to receive RSV vaccine, responses suggested safety concerns.
Strong recommendations for receiving RSV vaccine during pregnancy from a healthcare provider incorporating information about RSV vaccine safety and effectiveness may increase vaccine uptake.
Publisher
Elsevier Ltd,Elsevier Limited
Subject
/ Adult
/ Babies
/ Consent
/ Female
/ Health Knowledge, Attitudes, Practice
/ Humans
/ Medicaid
/ nationalities and ethnic groups
/ Patient Acceptance of Health Care
/ Pregnant People - psychology
/ Respiratory Syncytial Virus Infections - prevention & control
/ Respiratory Syncytial Virus Vaccines - administration & dosage
/ Respiratory Syncytial Virus, Human - immunology
/ Survey
/ Surveys
/ Vaccination - statistics & numerical data
/ Vaccines
/ variance
